However, the company reported an 8 percent decrease in net income to $18.3 million. The company’s president and CEO Brian Concannon said the company is still recovering from the OrthoPAT recall and continues to resolve its quality issues. The company’s plasma and blood management solutions business lines experienced growth during this period.
Related Articles on Orthopedic Devices:
NuVasive Shares Rise After Judge’s Ruling
Zimmer’s 2.9% Sales Increase Driven by Foreign Markets
Interventional Spine Receives FDA Clearance for Spine Device
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.